Another trial evaluating the safety and efficacy of the combination of TRC105 with other chemotherapeutic agents (letrozole/everolimus) is currently ongoing on patients with advanced hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer (NCT02520063) [5]. The gene discussed is ERBB2; the disease is breast carcinoma.